Shares of Cassava Sciences SAVA plunged 32.1% on Tuesday after the company announced that its lead pipeline candidate, ...

While investigations into the drug are stopping in Alzheimer’s disease, the therapy is now being evaluated in TSC-related ...

The company ended 2024 with just under $127 million in cash reserves, and nothing in its pipeline beyond the Alzheimer's ...

Cassava Sciences is ending simufilam development for Alzheimer's after Phase 3 trials failed. The company is shifting focus ...

US biotech Cassava Sciences (Nasdaq: SAVA) will shut down development of its lead Alzheimer’s disease candidate, simufilam, after the treatment failed a second late-stage trial. Top-line results from ...

Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets soluble amyloid beta oligomers (AβOs) for the treatment of Alzheimer ...

Cassava Sciences (SAVA) shared topline results from the Phase 3 REFOCUS-ALZ study of simufilam in mild-to-moderate AD. Topline data indicate ...

Cassava Sciences has given up on simufilam in Alzheimer’s disease. | Cassava Sciences has given up on simufilam in ...

REGIONS NEWS Simufilam did not show a significant reduction in co-primary endpoints of cognitive or functional decline versus ...

based on the DAS-COG12 and ADCS-ADL scales. Despite maintaining a favorable safety profile, the drug’s inability to demonstrate efficacy has dashed hopes for an alternative to existing Alzheimer ...

as assessed by the ADAS-COG12 and ADCS-ADL scales. The study failed to meet any pre-specified secondary and exploratory biomarker endpoints, as well. Based on the above study results, SAVA also ...